BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mas E, Barden A, Burke V, Beilin LJ, Watts GF, Huang RC, Puddey IB, Irish AB, Mori TA. A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Clin Nutr 2016;35:331-6. [PMID: 25908532 DOI: 10.1016/j.clnu.2015.04.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Small M, Serhan CN, Libreros S, Nshimiyimana R. E-series Resolvin Metabolome, Biosynthesis and Critical Role of Stereochemistry of Specialized Pro-Resolving Mediators (SPMs) in Inflammation-Resolution: Preparing SPMs for Long COVID-19, Human Clinical Trials, and Targeted Precision Nutrition. Seminars in Immunology 2022. [DOI: 10.1016/j.smim.2022.101597] [Reference Citation Analysis]
2 Mazzocchi A, De Cosmi V, Risé P, Milani GP, Turolo S, Syrén ML, Sala A, Agostoni C. Bioactive Compounds in Edible Oils and Their Role in Oxidative Stress and Inflammation. Front Physiol 2021;12:659551. [PMID: 33995124 DOI: 10.3389/fphys.2021.659551] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Vartak T, Godson C, Brennan E. Therapeutic potential of pro-resolving mediators in diabetic kidney disease. Adv Drug Deliv Rev 2021;178:113965. [PMID: 34508793 DOI: 10.1016/j.addr.2021.113965] [Reference Citation Analysis]
4 Eide IA, Reinholt FP, Jenssen T, Hartmann A, Schmidt EB, Åsberg A, Bergan S, Brabrand K, Svensson M. Effects of marine n-3 fatty acid supplementation in renal transplantation: A randomized controlled trial. Am J Transplant 2019;19:790-800. [PMID: 30125457 DOI: 10.1111/ajt.15080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
5 Mozurkewich EL, Greenwood M, Clinton C, Berman D, Romero V, Djuric Z, Qualls C, Gronert K. Pathway Markers for Pro-resolving Lipid Mediators in Maternal and Umbilical Cord Blood: A Secondary Analysis of the Mothers, Omega-3, and Mental Health Study. Front Pharmacol 2016;7:274. [PMID: 27656142 DOI: 10.3389/fphar.2016.00274] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
6 Dalli J, Serhan C. Macrophage Proresolving Mediators-the When and Where. Microbiol Spectr 2016;4. [PMID: 27337457 DOI: 10.1128/microbiolspec.MCHD-0001-2014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
7 Chiang N, Serhan CN. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med 2017;58:114-29. [PMID: 28336292 DOI: 10.1016/j.mam.2017.03.005] [Cited by in Crossref: 138] [Cited by in F6Publishing: 134] [Article Influence: 27.6] [Reference Citation Analysis]
8 Yong K, Mori T, Chew G, Beilin LJ, Puddey I, Watts GF, Irish A, Dogra G, Boudville N, Lim W. The Effects of OMEGA-3 Fatty Acid Supplementation Upon Interleukin-12 and Interleukin-18 in Chronic Kidney Disease Patients. J Ren Nutr 2019;29:377-85. [PMID: 30803749 DOI: 10.1053/j.jrn.2019.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Barden AE, Shinde S, Burke V, Puddey IB, Beilin LJ, Irish AB, Watts GF, Mori TA. The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease. Prostaglandins Other Lipid Mediat 2018;136:1-8. [PMID: 29577973 DOI: 10.1016/j.prostaglandins.2018.03.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
10 Verma S, Singh P, Khurana S, Ganguly NK, Kukreti R, Saso L, Rana DS, Taneja V, Bhargava V. Implications of oxidative stress in chronic kidney disease: a review on current concepts and therapies. Kidney Res Clin Pract 2021;40:183-93. [PMID: 34078023 DOI: 10.23876/j.krcp.20.163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Serhan CN, Chiang N, Dalli J. New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Mol Aspects Med 2018;64:1-17. [PMID: 28802833 DOI: 10.1016/j.mam.2017.08.002] [Cited by in Crossref: 92] [Cited by in F6Publishing: 106] [Article Influence: 18.4] [Reference Citation Analysis]
12 Pascoal LB, Palma BB, Chaim FHM, de Castro MM, Damázio TA, Franceschini APMF, Milanski M, Velloso LA, Leal RF. New translational and experimental insights into the role of pro-resolving lipid mediators in inflammatory bowel disease. World J Exp Med 2022; 12(1): 1-15 [DOI: 10.5493/wjem.v12.i1.1] [Reference Citation Analysis]
13 Barnig C, Bezema T, Calder PC, Charloux A, Frossard N, Garssen J, Haworth O, Dilevskaya K, Levi-Schaffer F, Lonsdorfer E, Wauben M, Kraneveld AD, Te Velde AA. Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease. Front Immunol 2019;10:1699. [PMID: 31396220 DOI: 10.3389/fimmu.2019.01699] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
14 Turolo S, Edefonti A, Syren ML, Marangoni F, Morello W, Agostoni C, Montini G. Fatty Acids in Nephrotic Syndrome and Chronic Kidney Disease. J Ren Nutr 2018;28:145-55. [PMID: 29153556 DOI: 10.1053/j.jrn.2017.08.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
15 Méndez L, Dasilva G, Taltavull N, Romeu M, Medina I. Marine Lipids on Cardiovascular Diseases and Other Chronic Diseases Induced by Diet: An Insight Provided by Proteomics and Lipidomics. Mar Drugs 2017;15:E258. [PMID: 28820493 DOI: 10.3390/md15080258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
16 See VHL, Mas E, Prescott SL, Beilin LJ, Burrows S, Barden AE, Huang RC, Mori TA. Effects of postnatal omega-3 fatty acid supplementation on offspring pro-resolving mediators of inflammation at 6 months and 5 years of age: A double blind, randomized controlled clinical trial. Prostaglandins Leukot Essent Fatty Acids 2017;126:126-32. [PMID: 29031390 DOI: 10.1016/j.plefa.2017.08.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
17 Hall WL. The future for long chain n-3 PUFA in the prevention of coronary heart disease: do we need to target non-fish-eaters? Proc Nutr Soc 2017;76:408-18. [PMID: 28508737 DOI: 10.1017/S0029665117000428] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
18 Ruperto M, Rodríguez-Mendiola N, Díaz-Domínguez M, Giménez-Moyano S, García-Bermejo ML, Fernández-Lucas M. Effect of oral administration of docohexanoic acid on anemia and inflammation in hemodialysis patients: A randomized controlled clinical trial. Clin Nutr ESPEN 2021;41:129-35. [PMID: 33487255 DOI: 10.1016/j.clnesp.2020.12.004] [Reference Citation Analysis]
19 Barden A, O'Callaghan N, Burke V, Mas E, Beilin LJ, Fenech M, Irish AB, Watts GF, Puddey IB, Huang RC, Mori TA. n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease. Nutrients 2016;8:175. [PMID: 27007392 DOI: 10.3390/nu8030175] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
20 Layé S, Nadjar A, Joffre C, Bazinet RP. Anti-Inflammatory Effects of Omega-3 Fatty Acids in the Brain: Physiological Mechanisms and Relevance to Pharmacology. Pharmacol Rev 2018;70:12-38. [PMID: 29217656 DOI: 10.1124/pr.117.014092] [Cited by in Crossref: 157] [Cited by in F6Publishing: 129] [Article Influence: 31.4] [Reference Citation Analysis]
21 Dasilva G, Medina I. Lipidomic methodologies for biomarkers of chronic inflammation in nutritional research: ω-3 and ω-6 lipid mediators. Free Radic Biol Med 2019;144:90-109. [PMID: 30902758 DOI: 10.1016/j.freeradbiomed.2019.03.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
22 Nienaber A, Hayford FEA, Variava E, Martinson N, Malan L. The Manipulation of the Lipid Mediator Metabolism as Adjunct Host-Directed Therapy in Tuberculosis. Front Immunol 2021;12:623941. [PMID: 33777003 DOI: 10.3389/fimmu.2021.623941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zaloga GP. Narrative Review of n-3 Polyunsaturated Fatty Acid Supplementation upon Immune Functions, Resolution Molecules and Lipid Peroxidation. Nutrients 2021;13:662. [PMID: 33670710 DOI: 10.3390/nu13020662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Welty FK. New Areas of Interest: Is There a Role for Omega-3 Fatty Acid Supplementation in Patients With Diabetes and Cardiovascular Disease? Curr Diab Rep 2019;19:6. [PMID: 30684085 DOI: 10.1007/s11892-019-1126-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 See VHL, Mas E, Prescott SL, Beilin LJ, Burrows S, Barden AE, Huang RC, Mori TA. Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: a double-blind, randomised controlled clinical trial. Br J Nutr 2017;118:971-80. [PMID: 29173199 DOI: 10.1017/S0007114517002914] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
26 Markworth JF, Kaur G, Miller EG, Larsen AE, Sinclair AJ, Maddipati KR, Cameron-Smith D. Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid. FASEB J 2016;30:3714-25. [PMID: 27461565 DOI: 10.1096/fj.201600360R] [Cited by in Crossref: 55] [Cited by in F6Publishing: 25] [Article Influence: 9.2] [Reference Citation Analysis]
27 Calder PC. Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake. Biochimie 2020;178:105-23. [PMID: 32860894 DOI: 10.1016/j.biochi.2020.08.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
28 Mori TA. Marine OMEGA-3 fatty acids in the prevention of cardiovascular disease. Fitoterapia 2017;123:51-8. [PMID: 28964873 DOI: 10.1016/j.fitote.2017.09.015] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 9.2] [Reference Citation Analysis]
29 Brennan E, Mohan M, Andrews D, Bose M, Kantharidis P. Specialized pro-resolving mediators in diabetes: novel therapeutic strategies. Clinical Science 2019;133:2121-41. [DOI: 10.1042/cs20190067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
30 Signorini L, Granata S, Lupo A, Zaza G. Naturally Occurring Compounds: New Potential Weapons against Oxidative Stress in Chronic Kidney Disease. Int J Mol Sci 2017;18:E1481. [PMID: 28698529 DOI: 10.3390/ijms18071481] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
31 Sharma M, Singh V, Sharma R, Koul A, Mccarthy ET, Savin VJ, Joshi T, Srivastava T. Glomerular Biomechanical Stress and Lipid Mediators during Cellular Changes Leading to Chronic Kidney Disease. Biomedicines 2022;10:407. [DOI: 10.3390/biomedicines10020407] [Reference Citation Analysis]
32 Borow KM, Mason RP, Vijayaraghavan K. Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A Review. Cardiorenal Med 2017;8:18-30. [PMID: 29344023 DOI: 10.1159/000479391] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
33 Ramos MFP, Oliveira OB, de Barros ADCMM, Razvickas CV, Pessoa EA, da Silva RF, Pereira AMS, Convento MB, Borges FT, Schor N. Comparison of olive leaf, olive oil, palm oil, and omega-3 oil in acute kidney injury induced by sepsis in rats. PeerJ 2019;7:e7219. [PMID: 31333903 DOI: 10.7717/peerj.7219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Wilusz M, Cieniawski D, Wasilewski G, Kuźniewski M, Sułowicz W, Sztefko K. Fatty acids profile in patients after heart or renal transplantation who developed metabolic complications. Adv Med Sci 2018;63:367-73. [PMID: 30125818 DOI: 10.1016/j.advms.2018.04.010] [Reference Citation Analysis]
35 de Gaetano M, McEvoy C, Andrews D, Cacace A, Hunter J, Brennan E, Godson C. Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications. Front Pharmacol 2018;9:1488. [PMID: 30618774 DOI: 10.3389/fphar.2018.01488] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
36 Velenosi TJ, Hennop A, Feere DA, Tieu A, Kucey AS, Kyriacou P, McCuaig LE, Nevison SE, Kerr MA, Urquhart BL. Untargeted plasma and tissue metabolomics in rats with chronic kidney disease given AST-120. Sci Rep 2016;6:22526. [PMID: 26932318 DOI: 10.1038/srep22526] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
37 Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions 2017;45:1105-15. [DOI: 10.1042/bst20160474] [Cited by in Crossref: 366] [Cited by in F6Publishing: 192] [Article Influence: 73.2] [Reference Citation Analysis]
38 Xu Y, Yang G, Zuo X, Gao J, Jia H, Han E, Liu J, Wang Y, Yan H. A systematic review for the efficacy of coenzyme Q10 in patients with chronic kidney disease. Int Urol Nephrol 2021. [PMID: 33782820 DOI: 10.1007/s11255-021-02838-2] [Reference Citation Analysis]
39 Mori TA. Reprint of: Marine OMEGA-3 fatty acids in the prevention of cardiovascular disease. Fitoterapia 2018;126:8-15. [PMID: 29657077 DOI: 10.1016/j.fitote.2018.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
40 Arnardottir HH, Dalli J, Norling LV, Colas RA, Perretti M, Serhan CN. Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation. J Immunol 2016;197:2362-8. [PMID: 27534559 DOI: 10.4049/jimmunol.1502268] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 11.0] [Reference Citation Analysis]
41 Shirooie S, Nabavi SF, Dehpour AR, Belwal T, Habtemariam S, Argüelles S, Sureda A, Daglia M, Tomczyk M, Sobarzo-Sanchez E, Xu S, Nabavi SM. Targeting mTORs by omega-3 fatty acids: A possible novel therapeutic strategy for neurodegeneration? Pharmacol Res 2018;135:37-48. [PMID: 29990625 DOI: 10.1016/j.phrs.2018.07.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
42 Syren ML, Turolo S, Marangoni F, Milani GP, Edefonti A, Montini G, Agostoni C. The polyunsaturated fatty acid balance in kidney health and disease: A review. Clin Nutr 2018;37:1829-39. [PMID: 29254659 DOI: 10.1016/j.clnu.2017.11.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
43 Serhan CN. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms. FASEB J. 2017;31:1273-1288. [PMID: 28087575 DOI: 10.1096/fj.201601222r] [Cited by in Crossref: 282] [Cited by in F6Publishing: 158] [Article Influence: 56.4] [Reference Citation Analysis]
44 Balas L, Risé P, Gandrath D, Rovati G, Bolego C, Stellari F, Trenti A, Buccellati C, Durand T, Sala A. Rapid Metabolization of Protectin D1 by β-Oxidation of Its Polar Head Chain. J Med Chem 2019;62:9961-75. [PMID: 31626541 DOI: 10.1021/acs.jmedchem.9b01463] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]